Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal.

Is it the right moment to include hyperthermic intraperitoneal chemotherapy as standard in ovarian cancer management? A reappraisal. J BUON. 2018 Dec;23(7):19-23 Authors: Samartzis K, Thomakos N, Liontos M, Kollia D, Malakasis A, Haidopoulos D, Bamias A, Rodolakis A, Loutradis D Abstract Ovarian cancer is a leading cause of cancer-related death in women and often is diagnosed at an advanced stage with diffuse peritoneal carcinomatosis. Since it is mainly confined to the peritoneal cavity, even after recurrence, it is an ideal target for loco-regional therapy. The standard therapeutic strategy of advanced ovarian cancer is cytoreductive surgery followed by systemic chemotherapy. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. Hyperthermic intraperitoneal chemotherapy (HIPEC) has several advantages over simple intraperitoneal chemotherapy. This has prompted the use of cytoreductive surgery (CRS) followed by HIPEC in the management of ovarian cancer as a part of first and second line treatment for recurrent disease. PMID: 30722107 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research